What is it about?
Safety of a trial design in lupus that eliminates polypharmacy and evidence of the confusion the polypharmacy may be inducing as background noise in clinical trials
Featured Image
Read the Original
This page is a summary of: The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials, Arthritis & Rheumatology, May 2017, Wiley,
DOI: 10.1002/art.40086.
You can read the full text:
Contributors
The following have contributed to this page
